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ABSTRACT
There are many challenges associated with characterizing
and quantifying cells for use in cell- and tissue-based thera-
pies. From a regulatory perspective, these advanced treat-
ments must not only be safe and effective but also be made
by high-quality manufacturing processes that allow for on-
time delivery of viable products. Although sterility assays
can be adapted from conventional bioprocessing, cell- and
tissue-based therapies require more stringent safety assess-
ments, especially in relation to use of animal products,
immune reaction, and potential instability due to extended
culture times. Furthermore, cell manufacturers who plan to
use human embryonic stem cells in their therapies need to
be particularly stringent in their ﬁnal puriﬁcation steps,
due to the unrestricted growth potential of these cells. This
review summarizes the current issues in characterization
and quantiﬁcation for cell- and tissue-based therapies,
dividing these challenges into the regulatory themes of
safety, potency, and manufacturing quality. It outlines cur-
rent assays in use, as well as highlights the limits of many of
these product release tests. Mode of action is discussed,
with particular reference to in vitro surrogate assays that
can be used to provide information to correlate with pro-
posed in vivo patient efﬁcacy. Importantly, this review
highlights the requirement for basic research to improve
current knowledge on the in vivo fate of these treatments;
as well as an improved stakeholder negotiation process to
identify the measurement requirements that will ensure the
manufacture of the best possible cell- and tissue-based
therapies within the shortest timeframe for the most patient
beneﬁt. STEM CELLS 2010;28:996–1004
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INTRODUCTION
Cell- and tissue-based therapies have the potential to treat
many conditions where present conventional treatments are
inadequate. As such, public expectation remains high that
these novel therapies will be ‘‘all curing,’’ even though there
have been few completed human trials, and such treatments
are currently only available in countries where the regulatory
burden is less stringent [1]. In the U.S. alone, there are cur-
rently over 750 clinical trials seeking volunteers for studies
that include the words ‘‘stem cell transplant*’’ in the interven-
tion [2]. Furthermore, current public policy remains uncertain,
as both scientists and regulators strive to set out a clear set of
criteria that is appropriate for all aspects of these products.
Therefore, there is still a signiﬁcant gap between promising
laboratory-based research and approved ﬁnal products in this
emerging ﬁeld. Keeping this in mind, this review aims to out-
line the three main product characteristics—safety, product
potency, and manufacturing quality. Next, current measure-
ment precision is analyzed, along with issues of assay sensi-
tivity, detection time, and total cost. Manufacturing challenges
are then identiﬁed, with an emphasis on regulatory subtleties.
Finally, summary perspectives are given on how developers
of cell- and tissue-based therapies can move forward in the
negotiation processes required in product development.
In terms of cell- and tissue-based products, both scientists
and entrepreneurs are focusing on a number of design and de-
velopment processes to ensure product success. The current
approach to cell- and tissue-based therapy development
involves using tightly controlled isolation, expansion, and
sorting processes to maintain a high-quality product. In this
situation, the required cell speciﬁcations are set at the begin-
ning of the process, with speciﬁc culture conditions set and
then maintained to ensure product consistency. One of the
disadvantages of this technique is that the critical quality
measurements are still unknown, making it difﬁcult to select
appropriate product release tests and optimize clinical efﬁ-
cacy. As our understanding of these advanced products
improves, an ‘‘ideal’’ product design process would involve
using the product’s mode of action to successfully tailor the
product speciﬁcations to provide a positive clinical outcome
(Fig. 1). However, deﬁning a mode of action is complex, and
clinical trials are currently the only mechanism of improving
understanding of therapeutic action in man. In consequence,
there is likely to be frequent iteration of product
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ﬁnition of product requirements and associated challenges
with regulatory approval may cause long delays to product
launch and provide signiﬁcant challenges to developers of
these advanced therapies.
Once a potential cell- or tissue-based therapy has been
identiﬁed, all stakeholders in the product development process
must be considered to ensure product success. In this review,
the stakeholders are broadly divided into three groups: the sci-
ence base, the entrepreneur, and the public policy actors. The
science base includes researchers involved with deﬁning prod-
uct evidence requirements, whether they are the initial
research ﬁndings identifying a potential therapy, or the later
development work involved with setting product speciﬁca-
tions. They are also responsible for collecting the necessary in
vitro and in vivo data for product understanding. These can
be scientists based at universities and public organizations, as
well as those working in both small-to-medium enterprises
(SMEs) and larger corporations. Their main motivation is to
increase the knowledge base surrounding the advanced ther-
apy. Next, the entrepreneur is the ﬁnancial force funding these
novel therapies. In most cases, the entrepreneur is the leader
of an SME, but can also include large pharma, venture capital
ﬁrms, and government funding bodies. Entrepreneurs, along
with investors, are critical in the development of this industry,
as they are more likely to fund an promising early-stage tech-
nology, whereas large pharma are only likely to become inter-
ested on successful completion of phase I trials. The entrepre-
neur must have a strong business case to support the cell- or
tissue-based product, and is most concerned with potential
revenues, as well as the creation of a suitable exit strategy for
the investor. Finally, the public policy actors are those
involved in the clinical aspects of the therapy, and include
regulators, reimbursers, clinicians, and patients. For these
clinical stakeholders, there is a strong motivation to bring
safe, potent, and cost-effective treatments to the general popu-
lation, with the rate of uptake of these therapies by clinicians
and patients strongly inﬂuenced by reimbursement. In this
stakeholder group, professional clinical bodies and patient ad-
vocacy groups can also inﬂuence therapy development and
approval through public awareness campaigns and govern-
ment lobbying.
PRODUCT SAFETY
In terms of the product itself, safety is the primary concern
for regulatory agencies when examining potential new treat-
ments. Following this, ensuring sterility is a priority for cell-
and tissue-based therapy manufacturers. Current Food and
Drug Administration (FDA) guidelines outline the require-
ments for microbiological testing of aerobic and anaerobic
bacteria and fungi (21 CFR 610.12). Since viable cell- and
tissue-based products cannot undergo a terminal sterilization
step, as is the case with other pharmaceuticals, they need to
be manufactured under aseptic conditions [3]. In addition,
these products are likely to have a short shelf-life, which of-
ten means that these products are administered to patients
before current sterility test results are available [4]. Because
of these obvious issues, there is a strong need to develop, val-
idate, and implement faster testing techniques than those cur-
rently accepted.
In terms of mycoplasma, the current testing standard for
mycoplasma contamination uses a broth and agar technique,
which simply analyses bacterial growth on nutrient media, as
described in the US 21 CFR 610.30. However, due to the
time constraints related to a short shelf-life, faster techniques
are being considered, for example, rapid microbiological
methods. This technique would provide the same performance
standards as are currently used in 21 CFR 610.30, but would
also provide these results in a much shorter time period, that
is, from weeks to hours [4]. Investigators can also choose to
validate polymerase chain reaction (PCR)-based mycoplasma
detection systems according to the guidelines of the FDA and
European Pharmacopoeias. Along with current PCR test kits,
Cambrex (East Rutherford, NJ, http://www.cambrex.com/)
currently produces a MycoAlert Mycoplasma Detection Kit
that claims to be able to detect <50 colony-forming units per
milliliter of mycoplasma, as well as providing results in less
Figure 1. Product design processes for cell- and tissue-based therapies. The top panel outlines the current approach to therapy design, where
the process is tightly controlled to maintain high quality. In the bottom panel, an ‘‘ideal’’ product process is outlined, where understanding of the
product’s mode of action tailors the speciﬁcations to provide a beneﬁcial clinical outcome.
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for the traditional broth and agar technique, this is a consider-
able improvement.
Viruses are another form of contamination that have to be
tested for before a product can be released. In terms of possi-
ble donor contamination, a donor blood sample can be ana-
lyzed for the presence of human immunodeﬁciency virus,
hepatitis B and C viruses, and human T-lymphotropic virus
[6]. However, there is also the possibility of viral contamina-
tion from reagents involved in the cell culture process, for
example, fetal calf sera (FCS) and porcine trypsin [7, 8]. It is
also important to note that many viruses have extended la-
tency periods, which means that a negative result at the time
of culture does not necessarily eliminate all patient risks [9].
In regards to transmissible spongiform encephalopathies, there
is manufacturing guidance regarding how to deal with possi-
ble risk products [3, 10]. Speciﬁcally, there must be a con-
stant traceability of animals, geographical limits on animals to
countries classiﬁed as geographical bovine spongiform ence-
phalopathy (BSE)-risk I and II [11], as well as speciﬁc animal
stunning methods [10].
Endotoxin or pyrogenicity testing is another requirement
of all parenteral drugs, biological products, cell- and tissue-
based therapies, and medical devices. This can be measured
by using one of two tests, either the rabbit pyrogen test
(USP151) or the limulus amebocyte lysate assay (USP85)
[12–14]. Validation of the individual test method must be
established (21 CFR 610.13), including whether the cell prep-
aration can interfere with the test selected [15]. Of note, it is
important to remember that some substances that have passed
these tests have still been shown to be pyrogenic in human
patients. Therefore, some suggest culturing in vitro human
blood mononuclear cells with the ﬁnal product, and injecting
this cell culture ﬂuid into rabbits to determine species-speciﬁc
pyrogenicity [16]. In terms of large-scale culture, there are
currently high throughput, FDA-licensed, rapid endotoxin test-
ing devices available, for example, Endosafe-MCS (Charles
River Laboratories, Wilmington, MA, http://www.criver.
com/), which have been used in conventional bioprocessing
applications.
There are many contributing factors that affect cellular
proliferation and survival. All cell culture conditions are
extremely important in maintaining large numbers of viable
cells [17]. Culture media can often be a difﬁcult choice, as
the majority available contains some animal products that
may increase the risk of disease transmission to the patient,
with various current good manufacturing practice (cGMP)
approved media in the literature [18–20]. However, all of
these preparations contain FCS, which is an animal-based
product that could potentially transfer disease, or even cause
immunogenic reactions in the patient [21, 22]. One study has
reported that patients receiving a hematopoietic stem cell
transplantation displayed antifetal calf serum antibodies,
which have also been found in normal human populations
[23]. Although they did not ﬁnd alloantibodies as a result of
sensitization to the mesenchymal stromal cells [23], it is im-
portant to try to reduce any potential patient risks by avoiding
the use of non-human products in culture. Therefore, autolo-
gous patient serum has been considered as an FCS replace-
ment [24]. However, in vitro studies have shown that sera
from aged patients can also inhibit cellular function [21, 25],
with young sera enhancing cell proliferation [26].
Knowledge regarding the body’s immune response to cell-
and tissue-based products will also inﬂuence the safety of the
product. If these products are recognized by the host as ‘‘for-
eign,’’ the risk of rejection and associated pathologies may be
greater than the potential beneﬁt to the patient [27]. In addition,
human leukocyte antigen (HLA) matching may be important in
pairing donors to hosts, since fewer HLA mismatches may lead
to better tissue acceptance [27, 28]. However, unlike organ
transplantations, not all cell- and tissue-based therapies may be
treating life-threatening conditions, which makes the use of
immune suppression drugs that may promote infection much
more difﬁcult to justify [29]. Therefore, the potential immune-
privileged state of human embryonic stem cells (hESCs) has
been discussed as a way to overcome these problems [29].
However, Drukker et al. have shown that although major histo-
compatibility complex-I expression is low in hESCs, it can be
rapidly induced, which could lead to rejection [30]. As a result,
there are still many issues surrounding host immune response
that have to be considered.
Since large number of cells are generally required for
administration, there is often a need to perform extensive in
vitro culturing over large periods [24]. However, this
extended ampliﬁcation time can also lead to cellular senes-
cence, as well as genetic and epigenetic changes [21, 24].
Karyotype testing should be performed once cells have been
maintained in culture for signiﬁcant periods to ensure chromo-
somal stability [31]. This can be achieved by counting a mini-
mum number of cells in a metaphase spread (>20) that has
been analyzed using Giemsa staining [32, 33]. If aneuploidies
are detected, the sample is immediately discarded removing
the need for further analysis. However, it is important to note
that standard genetic analysis only identiﬁes gross chromo-
somal abnormalities, and can miss submicroscopic DNA alter-
ations that can potentially affect cell phenotype [34]. Further-
more, there is very little knowledge about how these
abnormalities might be clinically signiﬁcant or their potential
risk to the patient. In terms of epigenetic aberrations, the pos-
sibility of irregular cell growth and potentially cancer is
always a major concern [24]. For treatments involving the use
of hESCs, the risk of undifferentiated cells contaminating the
eventual therapy is ever present. As a result, many authors
suggest that all undifferentiated and unwanted cells will need
to be removed before patient administration [35, 36].
PRODUCT POTENCY
Potency is deﬁned by the FDA as ‘‘the speciﬁc ability or
capacity of the product, as indicated by appropriate laboratory
tests or by adequately controlled clinical data obtained
through the administration of the product in the manner
intended, to effect a given result’’ [37]. Efﬁcacy generally
refers to the ability of a drug or medicinal treatment to cause
a functional response in the patient, and is proportional to the
potency of the therapy. Effective tests to determine product
potency will be required to ensure a cell- or tissue-based
product is manufactured to the same consistent standards [37].
With this in mind, proper characterization and understanding
of cell function, or mode of action, is the most important fac-
tor in determining whether a cell- or tissue-based therapy will
function effectively in vivo. However, as complete characteri-
zation of some cell processes are still unknown, it is very dif-
ﬁcult to accurately predict every consequence of a particular
cell once placed within a patient.
In terms of cell- and tissue-based products, unlike more
established pharmaceuticals, there will be continual feedback
to help inform the selection of in vitro efﬁcacy tests, as the
eventual fate of the cell once administered is still unknown.
As a result, initial release assays will be required to be based
on well understood in vitro data collected during cell charac-
terization and development. Preclinical safety studies and
nonclinical testing are also likely to provide further
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thermore, regulatory authorities require such in vivo testing to
identify safe dosages in humans, potential target organs for
toxicity, and safety parameters for clinical monitoring [38].
Although limited to the beginning of clinical development,
these nonclinical animal in vivo studies should also be sufﬁ-
cient to identify potential adverse affects that might then
occur in the ﬁrst in man clinical trial [39]. Leading on from
this, once manufacturers have approval to conduct clinical tri-
als and can correlate this data with in vitro product speciﬁca-
tions, improved product release tests will be designed and
integrated into the product development process. In addition,
once the product has been approved and used by a larger pop-
ulation, postmarketing surveillance will provide valuable
insights into the product mechanism. Therefore, clinical
results will provide expanded knowledge on in vivo mecha-
nisms, with the improved understanding of these mechanisms
allowing for better design of in vitro release tests, as shown
in Figure 2. However, these product release test improvements
are also going to be inﬂuenced by the resulting regulatory
implications.
Efﬁcacy tests should always be cell-speciﬁc, and ideally,
test the function of the cell that will be required in an in vivo
situation. For example, embryonic stem cell-derived cardiomy-
ocytes can be tested for function by analyzing spontaneous
beating of embryoid bodies in culture, or even by analyzing
levels of functional adrenoreceptors [40]. Preclinical in vivo
testing can provide enhanced product understanding and dem-
onstrate initial proof of concept, if issues such as the use of a
relevant animal species, age, physiological state, manner of
delivery, and stability of the test material are all carefully con-
sidered [38]. However, in some cases, in vitro assays can even
be more sensitive and give more useful data than in vivo trials
[41], especially when considering such issues as expense, vari-
ability, and time periods required for results [42]. As a result,
there are many issues concerning the ‘‘best’’ way to test for
product potency before reaching clinical trials, especially in
terms of whether in vitro efﬁcacy tests will act as successful
surrogates for predicting in vivo human clinical response.
Clinical endpoints have to be deﬁned at an early-stage to
allow for proper evaluation of cell- and tissue-based therapies
in patient trials. For example, for cardiac applications,
Losordo et al. used bioactivity measurements to assess the ef-
ﬁcacy of their CD34þ cell suspensions [43]. They evaluated
angina frequency, nitroglycerine use, exercise tolerance, sin-
gle-photon emission computed topography imaging, and qual-
ity of life testing [43]. Other groups have used enhanced myo-
cardial contractility and left ventricular ejection fractions,
both in relation to normal limits, as suitable endpoints for
their cardiac applications [44]. However, due to the complex-
ity of several clinical applications, optimal efﬁcacy measure-
ments may evolve over time due to improved clinical infor-
mation becoming available to inform the decision.
PRODUCT QUALITY THROUGH CONTROLLED
AND AUDITABLE MANUFACTURING PROCESSES
Cell Number and Viability
Once the manufacturer is certain that the product is safe, the
next step is to produce sufﬁcient quantities of cells to be thera-
peutically effective in a patient. In addition, although the num-
ber of cells produced is extremely important, the cell viability
itself is the primary concern for determining the actual cellular
effect in the body. This can be measured using various assays,
such as using trypan blue and a hemocytometer, as well as
more sophisticated measures of cell metabolic activity [45]—
with both providing quantitative data. Techniques such as ﬂow
cytometry [46] and multiplex assays [47] allow several parame-
ters to be measured at the same time. For large-scale manufac-
ture, automated cell counters, such as the Cedex (Innovartis,
Bielefeld, Germany, http://www.innovatis.com/), provide
increased cell count and viability accuracy, as well as large
time savings over traditional manual methods [48]. However,
most of these viability percentages simply measure how many
cells are ‘‘alive,’’ not how many cells are actively metabolizing
and playing a productive role in their environment.
Cryopreservation is a further point to consider when setting
cell number and viability speciﬁcations for cell- and tissue-
based products. Because of the inherent limitations of storing
and transporting actively growing cells, most product develop-
ers aim to cryopreserve their product to allow for long-term
product storage until the therapy is needed for patient adminis-
tration. Currently, the two main methods of preparing cells for
cryopreservation include slow-freezing with a permeating cryo-
protectant or vitriﬁcation, which involves partial replacement of
the water content of the cells with a cryoprotectant and then
rapid cooling by immersion in liquid nitrogen [49]. The main
problems associated with cryopreservation include loss of cell
numbers, decreased cell viability, and slower growth rates on
recovery. In addition, few cryopreservation protocols appear to
work well for hESCs [50]. The poor recovery rates post-thaw
can then lead to extended culture times, which have the possi-
bility of exerting selective pressure on the cells and conse-
quently expanding different hESC subpopulations in different
laboratories [50]. Therefore, it appears that more understanding
of the effects of cryopreservation, as well as a standardized pro-
tocol speciﬁc to hESCs, is urgently needed.
Cell Phenotype, Function, and Mode of Action
Cell phenotype is generally characterized through ﬂow cytom-
etry or ﬂuorescence-activated cell sorting, which can analyze
a cell’s stage of proliferation, differentiation, or activation
through cell surface and intracellular markers [51]. These
markers are commonly used to identify individual cell popula-
tions in heterogeneous samples. In terms of hESCs, Siti-Ismail
et al. state that they should be Oct-4þ, Nanogþ, stage-spe-
ciﬁc embryonic antigen-4þ, tumor rejection antigen (TRA)-1-
60þ, and TRA-1-81þ to maintain their ‘‘stemness’’ [52].
However, although biomarkers may be useful in distinguish-
ing different cell phenotypes, they do not always provide a
correlation to cell function. One example of this is that
patients with chronic ischemic cardiomyopathy have a similar
number of endothelial progenitor cells to healthy volunteers,
but their colony-forming ability is signiﬁcantly impaired [53].
Therefore, in terms of cell- and tissue-based therapies, how
the cells act in the body might be more important than their
immunophenotype in vitro.
Figure 2. Dynamic feedback process for determining effective in
vitro surrogates for release testing. As the eventual fate of the cell
once implanted is still unknown, continual feedback will be needed to
improve cell- and tissue-based therapy product design from the origi-
nal bench-based development through clinical trials and eventual
postmarketing surveillance.
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tions using various microscopy techniques to determine
whether cells appear true to their phenotype. For example,
ﬁbroblasts are commonly characterized by their elongated
spindle-shaped appearance when cultured in vitro [54]. In
addition, various stages of cellular senescence can be identi-
ﬁed through microscopy, which can be seen visually as
enlarged nuclei and multinucleated cells following extensive
culture of human epithelial cells [55]. There are several mi-
croscopy techniques available to analyze cellular morphology,
from ﬂuorescent confocal microscopy to wideﬁeld live cell
imaging [56]. Many companies are currently developing high
throughput and high-content screening platforms for auto-
mated analysis of cellular morphology, intracellular localiza-
tion, and cellular dynamics [56]. For example, Carl Zeiss
MicroImaging has a Cell Observer system that can acquire up
to 300 images/second, displays a resolution of 12 megapixels,
and has a signal to noise ratio of at least 1:2,500 [57]. How-
ever, these automated systems still require the user to deﬁne
their own parameters and analyze the images accordingly.
HOW PRECISELY CAN WE TAKE THESE
MEASUREMENTS?
Existing quantiﬁcation techniques for measuring safety param-
eters such as bacterial and fungal load, virus contamination,
and endotoxin levels appear to be sensitive enough to prevent
adverse patient events. Similarly, genetic testing is currently
precise enough to identify known gross chromosomal abnor-
malities, assuming that a sufﬁcient minimum number of meta-
phase spreads is counted [32]. However, the main drawbacks
of the current techniques are that they require long incubation
times and can be costly. Therefore, improvements in the proc-
essing times, reduction in costs, and conversion to automated
methods may improve the robustness of current contamination
detection methods. Furthermore, the main concern regarding
safety measurements is the current inability to remove all
unwanted cells. For this to occur, current cell detection meth-
ods will need to be sensitive enough to detect as few as tens
of cells in a large-cell suspension, for example, <0.00001%.
Considering that current advanced cell sorters claim to have
only a sensitivity limit of 98% [58], there need to be signiﬁ-
cant advances in this technology to ensure patient safety.
However, the multiple puriﬁcation steps required to ensure a
sufﬁcient standard of quality may add several costs on to the
product, in terms of reagents, work hours, and also initial cell
numbers required to give a puriﬁed product.
To meet product speciﬁcations, cell number and cell via-
bility measurements must be accurate so that speciﬁc product
dose can be determined. The accuracy of cell counts can also
be quite variable, with Brinkmann et al. reporting a 20%
counting error for manual cell counts, with only a 5% count-
ing error for the Cedex platform [59]. Therefore, although
automated cell counting systems have several advantages over
manual counting, improvements still need to be made. Of
note, the ﬁnal product acceptance range should be carefully
considered as the limitations of the machine must be taken
into account. This may include the tolerancing of machine
speciﬁcations, as well as factoring in measurement system
errors that may contribute to misleading data. An extremely
narrow range might cause products to be rejected due to these
inaccuracies rather than actual product failure. If an out-of-
speciﬁcation (OOS) result has occurred, FDA regulations
require a thorough, timely, unbiased, well-documented, and
scientiﬁcally sound investigation—even if the batch has been
rejected [60]. For products covered under approved full and
abbreviated drug applications, a ﬁeld alert report (FAR) must
be submitted within three working days of a OOS test result,
with a follow-up FAR submitted once the OOS investigation
is ﬁnalized [60]. Complementary to this procedure, the manu-
facturer needs to implement a corrective and preventive action
system to deal with complaints, product rejections, nonconfor-
mances, recalls, deviations, audits, regulatory inspections, and
ﬁndings, as well as process and product quality trends [61].
This system should be proportionate to the level of risk and
in line with ICH Q9, resulting in improvements in both the
product and process, along with enhanced product and process
understanding [61].
MANUFACTURING CHALLENGES
Issues concerning safety highlight the importance of manufac-
turers being able to maintain stringent compliance to cGMP
standards, as well as clear deﬁnition of these standards by the
appropriate regulatory authorities. However, once safety has
been addressed, the current biggest challenge for manufac-
turers of cell- and tissue-based therapies is in the development
of representative potency assays to evaluate the ﬁnal product.
According to a recent FDA guidance document, potency
assays must be speciﬁc, quantitative, meet predeﬁned criteria,
include appropriate standards and controls, be fully validated
and measure both identity and strength of all active ingre-
dients [37]. Therefore, due to the inherent heterogeneity in
the cell population, these requirements can only be met if the
product is fully deﬁned and manufactured to the same consist-
ent standards. This consistency will rely on strong quality sys-
tems controlling both the product and the manufacturing pro-
cess itself. One such quality system is quality by design,
which focuses on building quality into the product through a
thorough understanding of the process, combined with a clear
knowledge of manufacturing risks and mitigation strategies
[62]. This system can aid manufacturers by reducing time to
approvals, but can also build signiﬁcant cost into the manu-
facturing process through the shear amount of testing required
throughout production.
Product developers must also clearly identify when their
product release tests will take place, as speciﬁcations set for
products pre- or postcryopreservation may vary signiﬁcantly
and therefore prompt costly batch failures if not clearly
deﬁned. In most cases where cells are the ﬁnal product, man-
ufacturers will establish a two-tier system of a master cell
bank (MCB) and a working cell bank to ensure consistency of
the ﬁnal product. The MCB must be fully validated and
include the following information: the cell origin, standard
operating procedures for all manipulations, genetic and/or
phenotypic marker characterization, sterility testing, expiration
dating, and complete testing of thawed/expanded cells [15].
However, due to the potentially small cell numbers available,
alternative samples to the ﬁnal product may sometimes be
used to minimize product loss.
In terms of stability, the FDA has clear guidelines on test-
ing that must be performed to gain product approval.
Although these guidelines were originally developed for bio-
technological products, for example, proteins, they can be
adapted to include cell- and tissue-based products. In terms of
long-term cell storage and batch testing, manufacturers must
provide stability data on at least three batches that have
undergone manufacturing, but have not yet entered the
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ucts requiring long-term storage [63]. In addition, stability in-
formation should also be provided for at least three batches of
the drug product (manufactured in a manner that is representa-
tive of that used at scale). Finally, the manufacturer must gen-
erate a stability-indicating proﬁle that takes into account
changes in identity, purity, and potency of the ﬁnal product
[63].
Together with contamination, eliminating the potential for
cross-contamination is a major issue for manufacturers of
cell- and tissue-based therapies, especially if multiple autolo-
gous therapies are processed in the same laboratory at the
same time. Cell line cross-contamination has long been a con-
cern of those working in the area, with recent reports estimat-
ing cross-contamination levels of commercially available cell
lines between 18% and 36% [64]. The segregation of individ-
ual cell types, whether cell lines or individual patient cells, is
pivotal to maintaining quality of cell- and tissue-based prod-
ucts. However, in terms of manufacturing multiple autologous
therapies concurrently, the cost of complete segregation of
patients’ cells in dedicated incubators and biosafety cabinets
may make the cost of such therapies prohibitive for many
patients. Therefore, there are many distinct challenges to man-
ufacturers of autologous therapies, compared with those who
might only handle one distinct cell type for allogeneic
treatments.
Figure 3. General test process
for cell- and tissue-based thera-
pies. This process is divided
into the three main stages of
development, including safety,
efﬁcacy, and purity of manufac-
ture. In each stage, there are a
number of requirements that
must be met to allow the prod-
uct to continue through the next
stage of the process.
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As shown in this review, there are many issues to consider
when preparing a cell- and tissue-based therapy for commer-
cial use, with a general product process outlined in Figure 3.
This ﬂowchart includes a series of steps that must be com-
pleted before the product can be approved for human use. Ini-
tially, safety testing is critical, including assays for potential
microbial, fungal, endotoxin, mycoplasma, and viral contami-
nation; karyotype testing; and enrichment for the required cell
population. Once safety has been established, the product
must pass in vitro functional assays designed to act as surro-
gate measures for clinical effectiveness [65]. These potency
assays must be fully validated to meet regulatory require-
ments, including appropriate standards and controls. The third
stage of this process analyses whether the product has been
made to a certain set of speciﬁcations, and therefore ensures
the high quality of the process and the product. This generally
entails cell number and viability measurements, along with
cellular biomarkers that can act as identiﬁers of cell type and
purity. Once all of these categories have been addressed the
product should be suitable for human use, with continual post-
marketing surveillance after product launch to collect valuable
information that may further improve this process.
Depending on your perspective, all stakeholders have dif-
ferent requirements for these novel therapies. These poten-
tially conﬂicting perspectives and motivations will be difﬁcult
to condense into a singular solution that manages the risks,
rewards, and time to market for each treatment. In terms of
rewards, these can be returns to the entrepreneur, medical
beneﬁts to the patient, as well as ﬁnancial savings for the
healthcare providers, whether government or private organiza-
tions. Convergence on the risk/reward tradeoffs requires both
negotiation and a consensus on the evidence requirements for
product adoption. In this situation, the science base has a crit-
ical role in assisting both the deﬁnition of the evidence
requirements for the regulators, as well as working with clini-
cians to collect the necessary data to demonstrate in vivo
effectiveness. Hence, all of these needs will have to be bal-
anced according to the stakeholder’s inﬂuence on getting the
product to market (Fig. 4). Although scientiﬁc input is a key
mechanism for supplying robust data, commercial funding is
likely to be the primary determining factor in the develop-
ment of a successful product. In turn, a product can only be
available to the public after regulatory approval, which means
that public policy concerns regarding safety need to have pri-
ority, followed by cost-effectiveness. Clinician and patient
needs are also important, but as long as consultation is carried
out during product development, any concerns should be
addressed, at least to a certain extent, before full market
release. This negotiated approach to product development
should allow for all opinions to be noted, and then decisions
based on the stakeholder priority.
One major problem is that there are no current procedures
and scarce stakeholder resources for these negotiations. There-
fore, it appears that a common process will need to be devel-
oped to pool existing data and identify gaps in the informa-
tion required for informed discussion. Furthermore, as there is
still great debate over what measurements should be used to
conﬁrm these advanced therapies are safe and effective; scien-
tists need better resources to generate improved knowledge on
the in vivo fate of these treatments to inﬂuence measurement
selection. Therefore, as more in vivo data is gathered, and
safety proﬁles become easier to assess, product efﬁciency
should improve greatly from ﬁrst- to second- to third-genera-
tion products. Hopefully, the clinician and the patient will be
willing to wait for these more effective cell- and tissue-based
therapies.
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